Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Total Receivables
Fluoguide AS
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Total Receivables
kr6.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Receivables
kr6.2B
|
CAGR 3-Years
36%
|
CAGR 5-Years
48%
|
CAGR 10-Years
52%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Receivables
kr245.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
77%
|
CAGR 10-Years
25%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Receivables
€50.4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
75%
|
CAGR 10-Years
43%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Receivables
kr1.1B
|
CAGR 3-Years
44%
|
CAGR 5-Years
59%
|
CAGR 10-Years
25%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Receivables
kr13.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Total Receivables?
Total Receivables
6.4m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Total Receivables amounts to 6.4m DKK.
What is Fluoguide AS's Total Receivables growth rate?
Total Receivables CAGR 3Y
7%
Over the last year, the Total Receivables growth was -28%. The average annual Total Receivables growth rates for Fluoguide AS have been 7% over the past three years .
You don't have any saved screeners yet
